| Literature DB >> 29118714 |
Yun Qian1,2, Jialin Song1,2, Yuanming Ouyang1,2, Qixin Han3, Wei Chen1,2, Xiaotian Zhao4, Yangmei Xie5, Yinghui Chen5, Weien Yuan4, Cunyi Fan1.
Abstract
miR-132 is an endogenous small RNA and controls post-transcriptional regulation of gene expression via controlled degradation of mRNA or transcription inhibition. In the nervous system, miR-132 is significant for regulating neuronal differentiation, maturation and functioning, and widely participates in axon growth, neural migration, and plasticity. The miR-132 is affected by factors like mRNA expression, functional redundancy, and signaling cascades. It targets multiple downstream molecules to influence physiological and pathological neuronal activities. MiR-132 can influence the pathogenesis of many diseases, especially in the nervous system. The dysregulation of miR-132 results in the occurrence and exacerbation of neural developmental, degenerative diseases, like Alzheimer's disease, Parkinson's disease and epilepsy, neural infection and psychiatric disorders including disturbance of consciousness, cognition and memory, depression and schizophrenia. Regulation of miR-132 expression relieves symptoms, alleviates severity and finally effects a cure. This review aims to discuss the clinical potentials of miR-132 in the nervous system.Entities:
Keywords: axon growth; miR-132; nervous system diseases; neural migration; signaling pathways
Year: 2017 PMID: 29118714 PMCID: PMC5660991 DOI: 10.3389/fphar.2017.00770
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Relevance of miR-132 for various neuropathologies.
| Neuropathology | Direction of expression change | Validated target | Outcomes for changes of miR-132 expression | Reference | |
|---|---|---|---|---|---|
| Multiple sclerosis | Up-regulation | Sirtuin-1 | Induced the sharp increase in the proinflammatory factors LT and TNF-α | ||
| Alzheimer’s disease | Down-regulation | PTEN, FOXO3a | Caused TUNEL-positive neuron accumulation and caspase-dependent apoptosis | ||
| Parkinson’s disease | Up-regulation | Nurr1 | Affected the midbrain dopamine projections with the disruption of dopamine transmission in the basal ganglia | ||
| Progressive supranuclear palsy | Down-regulation | PTBP2 | Caused abnormal intracellular deposits of the microtubule-associated protein tau | ||
| Virus infection | Up-regulation | FOXP1, FOXP2 | induced nervous system complications, such as encephalitis in VZV | ||
| Prion diseases | Up-regulation | NMDA | blocked synaptic N-methyl-D-aspartate (N-methyl-D-aspartic acid, NMDA) receptor signaling pathways to suppress the protection function | ||
| Parasite infection | Up-regulation | DRD1, DRD5, MAOA | Increased neuronal spine density but impaired novel object recognition and spatial memory | ||
| Epilepsy | Up-regulation | SOX11 | Aggravated neuronal damage after status epilepticus attacks | ||
| Disturbance of consciousness and cognition | Up-regulation | AChE, p250GAP | Imbalanced excessive axonal budding-related nerve damage | ||
| Memory disturbance | Up-regulation | Rac1, p250GAP | Disregulated the development for synaptic morphological structure of dendritic spines | ||
| Depression | Down-regulation | Not mentioned | severe damage to the loop transformation of excitatory synapses of new neurons in the adult brain | ||
| Schizophrenia | Up-regulation | Dnmt3a, Dpysl3, NR1 and GAD67 | Disturbed the pattern of gene expression in the PFC during adolescent neurodevelopment | ||